Fennec Pharma Files 2025 Proxy Statement
Ticker: FENC · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1211583
| Field | Detail |
|---|---|
| Company | Fennec Pharmaceuticals Inc. (FENC) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Fennec Pharma's 2025 proxy statement is out, detailing exec pay for Raykov & Hackman. Check it for governance insights.
AI Summary
Fennec Pharmaceuticals Inc. filed its DEF 14A on April 25, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key individuals mentioned include Mr. Raykov and Mr. Hackman, with compensation data for the fiscal years 2022, 2023, and 2024.
Why It Matters
This filing provides crucial insights into executive compensation and corporate governance decisions at Fennec Pharmaceuticals, which can influence investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can reveal changes in executive compensation or governance that may impact investor sentiment.
Key Numbers
- 20250425 — Filing Date (Date the DEF 14A was filed.)
- 20250603 — Period of Report (The period this filing pertains to.)
- 2024-12-31 — Fiscal Year End (The end date of the company's fiscal year.)
Key Players & Entities
- FENNEC PHARMACEUTICALS INC. (company) — Filer
- Mr. Raykov (person) — Board Member
- Mr. Hackman (person) — Board Member
- ADHEREX TECHNOLOGIES INC (company) — Former Company Name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide information to shareholders regarding the company's annual meeting, including details on executive compensation, director nominations, and other corporate governance matters.
Who are the key individuals whose compensation is detailed in this filing?
Key individuals whose compensation is detailed include Mr. Raykov and Mr. Hackman, with compensation data provided for the fiscal years 2022, 2023, and 2024.
When was Fennec Pharmaceuticals Inc. formerly known as Adherex Technologies Inc.?
Fennec Pharmaceuticals Inc. was formerly known as Adherex Technologies Inc. with a date of name change on 20021223.
What is the business address of Fennec Pharmaceuticals Inc.?
The business address of Fennec Pharmaceuticals Inc. is PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC 27709.
What is the SIC code for Fennec Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Fennec Pharmaceuticals Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Mr. Raykov regarding FENNEC PHARMACEUTICALS INC. (FENC).